Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.
暂无分享,去创建一个
M. Piris | J. Rodríguez-Peralto | L. Sánchez | M. Pollán | B. Pérez-Gómez | S. Alonso | R. Pajares | P. Ortiz | F. Martínez-Tello | Carlos Hortelano | M. Acuña | L. Sánchez | C. Hortelano
[1] D. Rimm,et al. Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome , 2003, International journal of cancer.
[2] Lydia Sánchez,et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. , 2003, Blood.
[3] Donald R. Miller,et al. Melanoma incidence and mortality among US whites, 1969-1999. , 2002, JAMA.
[4] D. Pinkel,et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. , 2002, Cancer research.
[5] L. Chin,et al. p16(Ink4a) in melanocyte senescence and differentiation. , 2002, Journal of the National Cancer Institute.
[6] M. Barbacid,et al. To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.
[7] M. Barbacid,et al. Invasive melanoma in Cdk4-targeted mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Mihm,et al. The Melanocytic Proliferations A Comprehensive Textbook Of Pigmented Lesions , 2001 .
[9] C. Cordon-Cardo,et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. , 2001, Cancer research.
[10] O. Kallioniemi,et al. Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.
[11] Yasodha Natkunam,et al. Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry , 2001, Modern Pathology.
[12] L. Chin,et al. Genetic dissection of melanoma pathways in the mouse. , 2001, Seminars in cancer biology.
[13] M. Lisanti,et al. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. , 2001, American journal of physiology. Cell physiology.
[14] L. Chin,et al. Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas , 2001, Molecular and Cellular Biology.
[15] W. Gerald,et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.
[16] L. Chin,et al. Murine models of malignant melanoma. , 2000, Molecular medicine today.
[17] J. Nesland,et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] K. Weinberg,et al. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[19] K. Hemminki,et al. Analysis of G1/S checkpoint regulators in metastatic melanoma , 2000, Genes, chromosomes & cancer.
[20] L. Akslen,et al. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] J. McNiff,et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.
[22] A. Cesinaro,et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. , 1999, The Journal of investigative dermatology.
[23] M. Piris,et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. , 1999, Blood.
[24] M. Lisanti,et al. Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells , 1999, The Journal of Biological Chemistry.
[25] V. Tron,et al. Expression of cell cycle regulators in human cutaneous malignant melanoma. , 1999, Melanoma research.
[26] J. Nesland,et al. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.
[27] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[28] G. Walker,et al. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets , 1998, Genes, chromosomes & cancer.
[29] D. English,et al. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. , 1998, The American Journal of dermatopathology.
[30] M. Lisanti,et al. Caveolins, a Family of Scaffolding Proteins for Organizing “Preassembled Signaling Complexes” at the Plasma Membrane* , 1998, The Journal of Biological Chemistry.
[31] D. Stoppa-Lyonnet,et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.
[32] Charles C. Wykoff,et al. Recombinant Expression of Caveolin-1 in Oncogenically Transformed Cells Abrogates Anchorage-independent Growth* , 1997, The Journal of Biological Chemistry.
[33] E. Hovig,et al. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.
[34] N. Hayward,et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.
[35] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[36] D. Baltimore,et al. Reduction of caveolin and caveolae in oncogenically transformed cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[38] L. Karnell,et al. The national cancer data base. Report on melanoma , 1994, Cancer.
[39] J C Briggs,et al. Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.
[40] R. Lew,et al. Epidemiology of cutaneous melanoma. An update. , 1991, Dermatologic clinics.
[41] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[42] A Breslow,et al. Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.
[43] Daan Brandenbarg. The National. , 1892 .